Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infants' Advil

This article was originally published in The Tan Sheet

Executive Summary

Whitehall-Robins' NDA 21-812/SE5-003 for ibuprofen oral suspension concentrated drops (50 mg/1.25 mL) is approved Jan. 12. The product is indicated for use in children ages 6-23 months. Whitehall currently markets a number of Children's Advil products in drop, suspension and tablet formulations. Infants' Advil will compete with McNeil Consumer Healthcare's Infants' Tylenol pain reliever and fever reducer products

You may also be interested in...



Infants' Advil

Expanded dosing of Whitehall-Robins' Pediatric Advil Drops, to be launched this year as Infants' Advil Concentrated Drops, will come in fruit flavor in .5 fl. oz. (15 mL) and .25 fl. oz. (7.5 mL) sizes. The alcohol-free product (ibuprofen oral suspension 50 mg/1.25 mL) is for ages 6-23 months; Pediatric Advil Drops are for 2-3 year-olds. Labeling for the new drops will provide a dosing chart specifying a 1.25 mL dose should be given to infants weighing 12 lb.-17 lb. or ages 6-11 months, and a 1.875 mL dose should be provided for those 18 lb.-23 lb. or 12-23 months. For those under six months, a doctor should be consulted before use, the label states. Whitehall filed the supplemental NDA for the product June 15, 1998. FDA approved it Jan. 12 (1"The Tan Sheet" Jan. 17, In Brief)

Infants' Advil

Expanded dosing of Whitehall-Robins' Pediatric Advil Drops, to be launched this year as Infants' Advil Concentrated Drops, will come in fruit flavor in .5 fl. oz. (15 mL) and .25 fl. oz. (7.5 mL) sizes. The alcohol-free product (ibuprofen oral suspension 50 mg/1.25 mL) is for ages 6-23 months; Pediatric Advil Drops are for 2-3 year-olds. Labeling for the new drops will provide a dosing chart specifying a 1.25 mL dose should be given to infants weighing 12 lb.-17 lb. or ages 6-11 months, and a 1.875 mL dose should be provided for those 18 lb.-23 lb. or 12-23 months. For those under six months, a doctor should be consulted before use, the label states. Whitehall filed the supplemental NDA for the product June 15, 1998. FDA approved it Jan. 12 (1"The Tan Sheet" Jan. 17, In Brief)

Infants' Advil

Expanded dosing of Whitehall-Robins' Pediatric Advil Drops, to be launched this year as Infants' Advil Concentrated Drops, will come in fruit flavor in .5 fl. oz. (15 mL) and .25 fl. oz. (7.5 mL) sizes. The alcohol-free product (ibuprofen oral suspension 50 mg/1.25 mL) is for ages 6-23 months; Pediatric Advil Drops are for 2-3 year-olds. Labeling for the new drops will provide a dosing chart specifying a 1.25 mL dose should be given to infants weighing 12 lb.-17 lb. or ages 6-11 months, and a 1.875 mL dose should be provided for those 18 lb.-23 lb. or 12-23 months. For those under six months, a doctor should be consulted before use, the label states. Whitehall filed the supplemental NDA for the product June 15, 1998. FDA approved it Jan. 12 (1"The Tan Sheet" Jan. 17, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel